Please assess the completion status of the following clinical trial:

Trial Title: Darbepoetin Alfa With or Without Intravenous (IV) Iron

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Active non myeloid malignancy(cies) including lymphocytic leukemias~* Received chemotherapy and expected to receive at least 8 additional weeks of cyclic cytotoxic chemotherapy~* Anemia due to chemotherapy (screening Hgb \<or = 10.0 g/dL)~* at least 18 years of age at screening~Exclusion Criteria:~* Acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or myelodysplastic syndromes (MDS)~* Other underlying hematologic disorder, which could cause anemia, other than a non myeloid malignancy~* Active bleeding~* Severe, unstable, active chronic inflammatory disease (eg ulcerative disease, peptic ulcer disease, rheumatoid arthritis)~* Active, unstable systemic or chronic infection~* Planned elective surgery during the study where significant blood loss is expected~* Unstable angina, or uncontrolled cardiac arrhythmia~* Uncontrolled hypertension (diastolic blood pressure \> 100 mmHg)~* History of pure red cell aplasia (PRCA)~* History of deep venous thrombosis~* Known positive human immunodeficiency virus (HIV) test or acquired immune deficiency syndrome (AIDS) status~* Any red-blood-cell (RBC) transfusion within 28 days before randomization and/or during screening~* Currently receiving thalidomide or lenalidomide without prophylactic anticoagulant therapy~* Currently receiving or planned to receive myeloablative radiation therapy~* Received bone marrow or stem cell transplant in the 6 months prior to screening or planned during the study~* Received any erythropoietic therapy within 28 days before randomization and/or during screening (eg rHuEPO or darbepoetin alfa)~* Known sensitivity to any erythropoietic agents, the investigational product or its excipients to be administered during this study~* Known sensitivity to iron administration~* Pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darbepoetin alfa 300 μg plus IV Iron (Type: EXPERIMENTAL): Darbepoetin alfa 300 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
- Darbepoetin alfa 300 μg (Type: EXPERIMENTAL): Darbepoetin alfa 300 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
- Darbepoetin alfa 500 μg (Type: EXPERIMENTAL): Darbepoetin alfa 500 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
- Darbepoetin alfa 500 μg plus IV Iron (Type: ACTIVE_COMPARATOR): Darbepoetin alfa 500 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).

Based on this trial design, predict the completion outcome and termination type (if applicable).